Physician profile
Kevin Quang
NPI 1356655898
$1,515.64
in general payments reported to CMS, 2019-2025
13 companies · $473 in 2025
The $473 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.72 · 2020: $143 · 2021: $128 · 2022: $251 · 2023: $317 · 2024: $168 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $421.86 | 2022-2025 | Precision7, Tryptyr, Dailies Total1 |
| Coopervision INC. | $306.36 | 2021-2025 | Myday Contact Lens |
| Oyster Point Pharma, INC. | $157.80 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $148.91 | 2020-2025 | Cequa |
| Lkc Technologies, INC. | $124.69 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.21 | 2020 | |
| Abbvie INC. | $73.84 | 2022-2025 | |
| Lombart Brothers, INC. | $46.09 | 2023 | Opd-III |
| Johnson & Johnson Vision Care, INC. | $39.63 | 2023-2025 | Acuvue |
| Optos, INC. | $35.72 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $23.42 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $15.46 | 2025 | Vyzulta |
| Allergan, INC. | $12.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Quang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.